Storm clouds gather for biotech flotations
Only seven drug developers managed to float on Western exchanges in the third quarter, and new issues in October have struggled, with Biontech the latest example.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
The contrasting fortunes of Envista and Smiledirectclub
Two dental companies go public inside a week, with very different results.
A recap on the past few months of data digging and analysis
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
Livongo enters the medtech float hall of fame
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Few medtechs go public, but those that do, do nicely
Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.
Back to business for biotech flotations
After a quiet first quarter demand for new issues has returned to levels seen in 2018, itself a record year for IPOs of young drug developers.
Looking back at April’s data digging and analysis
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.